Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, . . . Erich Rajkovic. (2021). Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. Taylor & Francis Group.
Chicago Style (17th ed.) CitationSusanne Wingert, et al. Preclinical Evaluation of AFM24, a Novel CD16A-specific Innate Immune Cell Engager Targeting EGFR-positive Tumors. Taylor & Francis Group, 2021.
MLA (9th ed.) CitationSusanne Wingert, et al. Preclinical Evaluation of AFM24, a Novel CD16A-specific Innate Immune Cell Engager Targeting EGFR-positive Tumors. Taylor & Francis Group, 2021.
Warning: These citations may not always be 100% accurate.